메뉴 건너뛰기




Volumn 57, Issue 7-8, 2009, Pages 509-510

The irrepressible rise of biomarkers in oncology

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; PANITUMUMAB; TRASTUZUMAB; TUMOR MARKER;

EID: 71549144789     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.11.001     Document Type: Editorial
Times cited : (1)

References (7)
  • 1
    • 41649100689 scopus 로고    scopus 로고
    • Mining the plasma proteome for cancer biomarkers
    • Hanash S.M., Pitteri S.J., and Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 452 (2008) 571-579
    • (2008) Nature , vol.452 , pp. 571-579
    • Hanash, S.M.1    Pitteri, S.J.2    Faca, V.M.3
  • 2
    • 33846595479 scopus 로고    scopus 로고
    • ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
    • Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24 (2006) 5313-5327
    • (2006) J Clin Oncol , vol.24 , pp. 5313-5327
    • Locker, G.Y.1    Hamilton, S.2    Harris, J.3
  • 3
    • 0037203764 scopus 로고    scopus 로고
    • The molecular outlook
    • Caldas C., and Aparicio S.A. The molecular outlook. Nature 415 (2002) 484-485
    • (2002) Nature , vol.415 , pp. 484-485
    • Caldas, C.1    Aparicio, S.A.2
  • 4
    • 36549068221 scopus 로고    scopus 로고
    • Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    • Bonnefoi H., Potti A., Delorenzi M., et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8 (2007) 1071-1078
    • (2007) Lancet Oncol , vol.8 , pp. 1071-1078
    • Bonnefoi, H.1    Potti, A.2    Delorenzi, M.3
  • 5
    • 36549067240 scopus 로고    scopus 로고
    • Breast cancer genomics: real-time use
    • Bertucci F., and Birnbaum D. Breast cancer genomics: real-time use. Lancet Oncol 8 (2007) 1045-1047
    • (2007) Lancet Oncol , vol.8 , pp. 1045-1047
    • Bertucci, F.1    Birnbaum, D.2
  • 6
    • 38149015568 scopus 로고    scopus 로고
    • Critical review of microarray-based prognostic tests and trials in breast cancer
    • Koscielny S. Critical review of microarray-based prognostic tests and trials in breast cancer. Curr Opin Obstet Gynecol 20 (2008) 47-50
    • (2008) Curr Opin Obstet Gynecol , vol.20 , pp. 47-50
    • Koscielny, S.1
  • 7
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lievre, A.1    Bachet, J.B.2    Le Corre, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.